ImmunoPrecise Antibodies price target lowered to $7 from $12 at Benchmark

Benchmark analyst Robert Wasserman lowered the firm’s price target on ImmunoPrecise Antibodies to $7 from $12 and keeps a Speculative Buy rating on the shares after the company reported financial results for their fiscal Q3. While the firm is maintaining its Speculative Buy rating on the shares, it is reducing its target due to lower market comparable valuations.